---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000056"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:56:51.893751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL

## Summary
- 67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.
- 5 of 7 complete responders maintained CR at 6 months; median DOR 23.1 months; 3 patients in remission >24 months, longest >31 months.
- No Grade 3+ CRS, ICANS, or GvHD; cytopenias and infections manageable; safety comparable to autologous CAR T.
- Pivotal Phase 2 ALPHA2 trial of ALLO-501A enrolling; expected enrollment completion in first half of 2024.

## SEC filing metadata
- accession: 0001737287-23-000056
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/0001737287-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/allo-20230603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000056
- JSON: https://secwatch.observer/filing/0001737287-23-000056.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.